Sandro Tonali’s agent has been busy over recent weeks. After reportedly offering his client to a Premier League rival and then denying such speculation, he proceeded to cast doubt over the Italian’s ...

Most Super Bowl commercials aim to be faster, louder and shinier than the rest. And then there are Big Game ads from advertisers like Coinbase. After mystifying Super Bowl viewers in 2022 with a ...

The agent of Newcastle United midfielder Sandro Tonali has admitted there will be talks over the Italian’s future at the end of the season after the Magpies declined to entertain the idea of a winter ...

Sky in Italy and Sky Sports News have both clarified that no such approach has been made, nor has any formal enquiry been lodged. That clarity has come directly from Tonali’s representative, Giuseppe ...

Penumbra has rolled out its first new system since Boston Scientific announced plans to acquire the company in a $14.5 billion cash and stock deal. The company has launched its Lightning Flash 3.0 ...

During Boston Scientific chief executive Mike Mahoney’s 13-year tenure, he has presided over more than 40 acquisitions so far. But this one is different, at least by size: Mahoney on Thursday unveiled ...

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as blood ...

We recently published 10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs. Penumbra Inc. (NYSE:PEN) was one of the top performers on Thursday. Penumbra soared to a new all-time high on Thursday, as ...

Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio. Boston Scientific on Thursday said the ...

The transaction values Penumbra at $374 per share, representing a roughly $14.5 billion enterprise value. Penumbra shareholders may elect to receive cash or Boston Scientific stock, with proration ...